4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS 106261-49-8 Imatinib Mesylate Intermediate High Purity

Short Description:

4-[(4-Methylpiperazin-1-yl)methyl]benzoic Acid Dihydrochloride

CAS: 106261-49-8

Appearance: White to Almost White Powder to Crystal

Purity: ≥98.0% (HPLC) 

Intermediate of Imatinib Mesylate (CAS: 220127-57-1) in the treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+CML)

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride
Synonyms Imatinib Mesylate Intermediate
CAS Number 106261-49-8
CAT Number RF-PI229
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C13H20Cl2N2O2
Molecular Weight 307.22
Melting Point 305.0~307.0℃
Solubility  Soluble in Water
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Almost White Powder to Crystal
Purity / Analysis Method ≥98.0% (HPLC)
Loss on Drying ≤0.50% 
Residue on ignition ≤0.50%
Total Impurities ≤2.0%
Maximum Single Impurity ≤1.0%
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediate of Imatinib Mesylate (CAS: 220127-57-1)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS: 106261-49-8) with high quality. It is an intermediate typically in the synthesis of Imatinib Mesylate (CAS: 220127-57-1). Imatinib Mesylate is a tyrosine kinase inhibitor, highly specific for BCR-ABL, an oral drug for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in the acute phase and certain forms of acute lymphoblastic leukemia (ALL), accelerated phase and chronic phase after failure of interferon therapy.  

  • Write your message here and send it to us